LONPROV Canadian Trademark Information
Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, stroke, cancer, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the prevention and/or treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparation for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics; pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories.
Perfect for these industries
Words that describe this mark
pharmaceutical preparations human use treatment prevention obesity diabetes incontinence cardiovascular diseases stroke cancer autoimmune diseases solid organ transplant rejection pharmaceutical preparations treatment respiratory pharmaceutical preparations prevention andor treatment metabolic disorders
Abandonment Notice!
On Wednesday, December 9, 2009,
status on the LONPROV
trademark changed to Interruption of proceeding.
Apply Now for this name starting at $449!
CAUTION: Although Canada registration for this particular filing is inactive,
the mark may still enjoy common law rights, or may have been applied for again in a separate application.
Further research may be warranted to determine where this mark is truly abandoned in commerce.
On Wednesday, November 15, 2006, a canadian trademark registration was filed for
LONPROV by Bristol-Myers Squibb Company
( *********, **********, ***** ****.
The Canadian IP office has given the trademark application number of
1324263.
The current status of this trademark filing is Interruption of proceeding.
The correspondent listed for
LONPROV is
GOWLING WLG (CANADA) LLP of *********, **********, ***** ****
The LONPROV
trademark is filed in the description of
Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, stroke, cancer, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the prevention and/or treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparation for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics; pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories.
.
100% Satisfaction Guarantee
protect your valuable brand now.
Classification Information